Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496257 | 1.00 | GPR119 (0.39) | GPR119CYP2C9CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL25282720 | 0.82 | GPR119 (0.38) | GPR119CYP2C9CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL30496247 | 0.82 | GPR119 (0.38) | GPR119CYP2C9CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL16150656 | 0.80 | ALDH1A1 (0.46) | CYP2C9CYP2C19NPSR1ALDH1A1MAPK1 | |
| SCHEMBL3759044 | 0.79 | ALDH1A1 (0.61) | CYP2C9CYP2C19NPSR1ALDH1A1MAPK1 | |
| SCHEMBL16149260 | 0.78 | CYP2C9 (0.44) | CYP2C9CYP2C19NPSR1ALDH1A1MAPK1 | |
| SCHEMBL30496249 | 0.75 | CYP2C9 (0.39) | CYP2C9CYP2C19NPSR1ALDH1A1MAPK1 | |
| SCHEMBL25289588 | 0.75 | CYP2C9 (0.39) | CYP2C9CYP2C19NPSR1ALDH1A1MAPK1 | |
| SCHEMBL26808076 | 0.75 | PDE4B (0.37) | GPR119ALDH1A1POLBNR3C2GLA | |
| SCHEMBL10073269 | 0.75 | CYP2C9 (0.40) | CYP2C9CYP2C19NPSR1ALDH1A1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| EP-4452984-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Molecure S.A. (PL) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | GPR119 3796/4885CYP2C9 3896/4885CYP2C19 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.